Publications: Dr David Holden
Ammoscato F, Wafa M, Skonieczna J, Bestwick J, Monero R, Andrews M, De Trane S, Holden D et al.
(
2024
)
.
Cladribine tablets in relapsing-remitting multiple sclerosis preferentially target B-cells
.
Clinical Immunology
vol.
269
,
Mousele C, Holden D, Gnanapavan S
(
2024
)
.
Neurofilaments in neurologic disease
.
vol.
123
,
Elsevier
Ammoscato F, Skonieczna J, Bestwick J, Holden D, Aboulwafa M, Andrews M, Turner B, Marta M et al.
(
2024
)
.
Prospective Longitudinal Study of Cladribine Tablets (CLADB Study) Demonstrates Sustained Reduction in Kappa Free Light Chains in Relapsing Multiple Sclerosis (RRMS) at 96 Weeks (P10-6.008)
.
Neurology
vol.
102
,
(
17_supplement_1
)
Dobson R
(
2023
)
.
A phase 2 open-label clinical trial to determine the effect of Famciclovir on Epstein-Barr virus activity as measured by EBV shedding in the saliva of patients with Multiple Sclerosis
.
Multiple Sclerosis Journal
Allen-Philbey K, De Trane S, MacDougall A, Adams A, Bianchi L, Campion T, Giovannoni G, Gnanapavan S et al.
(
2023
)
.
Disease activity 4.5 years after starting cladribine: experience in 264 patients with multiple sclerosis
.
Therapeutic Advances in Neurological Disorders
vol.
16
,
Gold J, Holden D, Parratt J, Yiannikas C, Ahmad R, Sedhom M, Giovannoni G
(
2022
)
.
Effect of teriflunomide on Epstein–Barr virus shedding in relapsing-remitting multiple sclerosis patients: Outcomes from a real-world pilot cohort study
.
Multiple Sclerosis and Related Disorders
.
vol.
68
,
Adams A, Tilden W, Bestwick J, Holden D, Bianchi L, Smets I, Giovannoni G, Gnanapavan S
(
2022
)
.
The relationship of cerebrospinal fluid neurofilament levels with magnetic resonance imaging lesion location and disease activity in multiple sclerosis
.
European Journal of Neurology
vol.
29
,
(
9
)
2754
-
2760
.
Smets I, Holden D, Bianchi L, Ammoscato F, Allen-Philbey K, Baker D, Turner B, Marta M et al.
(
2022
)
.
Factors contributing to CSF NfL reduction over time in people with multiple sclerosis starting treatment: an observational study
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
28
,
33
-
34
.
Smets I, Holden D, Bianchi L, Ammoscato F, Allen-Philbey K, Baker D, Turner B, Marta M et al.
(
2021
)
.
Factors contributing to CSF NfL reduction over time in those starting treatment for multiple sclerosis: An observational study
.
Multiple Sclerosis and Related Disorders
vol.
57
,
Smets I, Holden D, Bianchi L, Ammoscato F, Allen-Philbey K, Baker D, Turner B, Marta M et al.
(
2021
)
.
Factors contributing to CSF NfL reduction over time in people with multiple sclerosis starting treatment: an observational study
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
27
,
514
-
515
.
Schmierer K, Gnanapavan S, Giovannoni G, Ammoscato F, Holden D, Carrillo-Loza K, Christmas T, Bianchi L et al.
(
2020
)
.
CSF neurofilament light chain testing as an aid
to determine treatment strategies in MS
.
Neurology, Neuroimmunology and Neuroinflammation
vol.
7
,
(
6
)
Reyes S, Smets I, Holden D, Carrillo-Loza K, Christmas T, Bianchi L, Ammoscato F, Turner B et al.
(
2020
)
.
CSF neurofilament light chain testing as an aid to determine treatment strategies in MS
.
Neurology Neuroimmunology & Neuroinflammation
vol.
7
,
(
6
)
Smets I, Reyes S, Carrillo-Loza K, Mateo-Casas M, Bianchi L, Holden D, Ammoscato F, Turner B et al.
(
2020
)
.
CSF Neurofilament Light Chain for guiding individual treatment decisions in multiple sclerosis
.
EUROPEAN JOURNAL OF NEUROLOGY
.
vol.
27
,
475
-
476
.
Carrillo-Loza K, Reyes S, Bianchi L, Holden D, Espasandin M, Ammoscato F, Turner B, Schmierer K et al.
(
2019
)
.
Real Life Evidence for CSF Neurofilaments Light Chain in Clinical Practice. (P5.2-021)
.
Neurology
vol.
92
,
(
15_supplement
)
Reyes S, Carrillo-Loza K, Mateo M, Bianchi L, Holden D, Ammoscato F, Marta M, Turner B et al.
(
2019
)
.
Evidence of the utility of CSF neurofilament light chain measurements in people with MS in clinical practice
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
25
,
854
-
854
.
Carrillo-Loza K, Reyes S, Bianchi L, Holden D, Espasandin M, Ammoscato F, Turner B, Schmierer K et al.
(
2019
)
.
Real life Evidence for CSF Neurofilaments Light Chain in Clinical Practice
.
NEUROLOGY
.
vol.
92
,
Holden DW, Gold J, Hawkes CH, Giovannoni G, Saxton JM, Carter A, Sharrack B
(
2018
)
.
Epstein Barr virus shedding in multiple sclerosis: Similar frequencies of EBV in saliva across separate patient cohorts
.
Multiple Sclerosis and Related Disorders
vol.
25
,
197
-
199
.
Gold J, Marta M, Meier UC, Christensen T, Miller D, Altmann D, Holden D, Bianchi L et al.
(
2018
)
.
A phase II baseline versus treatment study to determine the efficacy of raltegravir (Isentress) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhanced MRI: The INSPIRE study
.
Multiple Sclerosis and Related Disorders
vol.
24
,
123
-
128
.
Gold J, Marta MC, Meier UC, Christensen T, Miller D, Altmann D, Holden D, Bianchi L et al.
(
2016
)
.
Phase 2 baseline versus treatment clinical trial of the HIV drug raltegravir in patients with active relapsing remitting multiple sclerosis: the INSPIRE study biomarker outcome results
.
MULTIPLE SCLEROSIS JOURNAL
.
Conference:
MSLondon (ACTRIMS/ECTRIMS) 2016
vol.
22
,
188
-
189
.
Marta M, MacManus D, Yousry T, Miller D, Altmann DR, Meier UC, Christensen T, Maruszak H et al.
(
2016
)
.
Phase 2 baseline versus treatment clinical trial of the HIV drug raltegravir in patients with active relapsing remitting multiple sclerosis: the INSPIRE study results
.
MULTIPLE SCLEROSIS JOURNAL
.
Conference:
MSLondon (ACTRIMS/ECTRIMS) 2016
vol.
22
,
188
-
188
.
Gold J, Giovannoni G, Marta MC, Meier U, Miller D, Christensen T, Maruszak H, Holden D et al.
(
2015
)
.
Pilot baseline versus treatment clinical trial of the HIV drug raltegravir in patients with active relapsing remitting multiple sclerosis: the INSPIRE study
.
MULTIPLE SCLEROSIS JOURNAL
.
vol.
21
,
162
-
162
.
Maghzi AH, Meier U, Holden D, Marta M, Kantor A, Waubant E, Giovannoni G, Goelz S
(
2009
)
.
Natural killer cell status in multiple sclerosis and its association with interferon beta-1a treatment
.
MULTIPLE SCLEROSIS
.
vol.
15
,
S73
-
S73
.